Having trouble viewing this email? View in your browser.
ESCMID Logo

24 September 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

ESCMID E-Library Highlight – 5th ESCMID Conference on Vaccines

Didn’t get a chance to make it to Bilbao earlier this month, or just want to re-live the great presentations and posters?

Find the conference material on the ESCMID E-Library now!

› Read more

Registration for the 30th ECCMID is now open!

Registration has now opened for the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), to be held in Paris, France, from 18-21 April, 2020.

Remember that all money from printed programme books will go towards supporting delegates that would otherwise not be able to attend.

ECCMID is the world’s premier meeting in the field of infection, drawing over 13,000 delegates from 130 countries in Amsterdam just this year.

Find out more and register on the Congress Website.

› Read more

ESCMID call for clinical practice guidelines projects 2019

The ESCMID Guideline Subcommittee invites ESCMID members and ESCMID Study Groups to submit proposals for clinical practice guidelines projects in the 4 priority topics identified by the first global survey among stakeholders in the infectious diseases, clinical microbiology and infection control field across the world. The (broad) topics are:

  • Antimicrobial stewardship
  • Diagnosis and management of influenza
  • Surgical prophylaxis and infection control means, in patients colonised by MDR pathogens before surgery
  • Diagnostic and treatment of non-hospitalized Community Acquired Pneumonia

Full details can be found in the call text (https://www.escmid.org) and in the newly released ESCMID manual for guidance documents. Deadline for project proposals is 31/10/2019. For any questions, please write to guidancedocuments@escmid.org.

› Read more
 

Meet ESCMID at the ERS International Congress 2019

If you are in Madrid to attend the ERS International Congress 2019, come and meet us in the World Village, Desk 20: we will be happy to answer your questions and listen to your expectations for the future of our society. ESCMID will not only be present in the World Village, but will also contribute to the scientific programme of the congress with the Symposium “Fighting antimicrobial resistance: from prevention to antimicrobial stewardship”, Sunday 29th, 10:45-12:15. Moreover, the ATS/ESCMID/ERS/IDSA clinical practice guideline will be presented in the session “New guidelines for treatment of nontuberculous mycobacterial pulmonary disease”, Monday 30th, 14:45-16:45. We look forward to seeing you!

› Read more
 

Join Good Clinical Practice Training in Greece

Are you a clinical or laboratory investigator working in Greece? On 15-16 October COMBACTE (Combatting Antimicrobial Resistance in Europe) in collaboration with EFGCP (European Forum for Good Clinical Practice) offers a free 2-day Good Clinical Practice (GCP) training in Athens, Greece for clinical research staff.

This is a great practical way to gain knowledge about GCP through interactive plenary sessions with our GCP experts from EFGCP and University Medical Center Utrecht, the Netherlands. You will be able to network with our experts, and fellow investigators from Greece.

You get the chance to learn more about COMBACTE’s unique clinical research network in Europe. By engaging a large pan-European network of clinical and laboratory centers, COMBACTE helps lay the foundations on which companies can build efficient and effective Phase II and Phase III trials for potential new antibacterial drugs. Pfizer, AstraZeneca, GSK, bioMérieux, Da Volterra, Janssen are some of the partners using COMBACTE’s clinical research network.

COMBACTE is a key project of the European Commissions’ New Drugs For Bad Bugs (ND4BB) program, which together with the Innovative Medicines Initiative (IMI) is part of the collaborative R&D efforts to tackle antimicrobial resistance.

EFGCP is the leading multi-stakeholder forum in Europe where science and ethics meet to promote Good Clinical Practice in biomedical research.

› Read more
 

Closing of applications for the ESCMID course on the development of clinical practice guidelines 2019.

We are pleased to announce that there have been a large number of applications for the first course on the development of clinical practice guidelines. Of these very high quality applications, only 20 ESCMID members will follow this event.

The knowledge acquired during the course should enable participants to actively participate in systematic reviews, meta-analyses and the development of guidance documents to high quality standards. This course will take place every year and we hope you will join us in the next session.

Please consult the ESCMID Directive website. We will update, propose and share information on the guidance document process. In addition, we will soon announce the possibility of becoming an advisory member of the ESCMID guidance document.

We look forward to receiving further quality proposals from you in the future.

› Read more
 

ESCMID/UEMS sign Berlin Declaration of physicians dedicated to the diagnosis and care of patients with lnfectious diseases.

On the occasion of the annual meeting of delegates, which took place in Berlin on September 20th and 21st, 2019, the Infectious Diseases Section of the European Union of Medical Specialists (UEMS-ID) presented the Berlin Declaration on the European perspectives of health policy aspects and especially on developments in Infectious Diseases. ESCMID was a signatory of the Declaration.

Read more about the declaration and see the Press Release on the ESCMID News page.

› Read more
 

CMI Highlight: Multistate population and whole genome sequence based strain surveillance of invasive pneumococci recovered in the United States during 2017

J. Varghese et al aimed to provide population and whole genome sequence (WGS)-based characterization of invasive pneumococcal disease (IPD) isolates collected from multistate surveillance in the United States during 2017.

The authors obtained short read WGS from 2881 isolates with associated bioinformatics pipeline strain feature predictions. For quality control, capsular serotypes and antimicrobial minimum inhibitory concentrations (MICs) were also obtained conventionally from 442 isolates. Annotated WGS was provided (inclusive of serotypes, MICs, multilocus sequence types, pilus type(s)) from 2723 isolates. For 158 isolates with suboptimal WGS, antimicrobial MICs were obtained conventionally.

There were 127 isolates from children <5 years and 2754 isolates from those > 5 in 2017. One of 43 different serotypes were predicted for 2877 of the 2881 isolates. Serotypes in 13-valent conjugate vaccine together with 6C (PCV13+6C) accounted for 816 (28.3%) isolates, with PCV13 serotype 3 being the most common serotype overall. Non-PCV13-6C- serotypes accounted for 2,065 (71.7%) isolates, comprising 96 (75.6%) isolates from children < 5 and 1969 (61.4%) isolates from those > 5. Of 36 different categories of recently emerged serotype-switch variants, three showed marked increases relative to 2015-2016 in that the number from 2017 surpassed the number from 2015-2016 combined. Two of these included antimicrobial-resistant serotype 11A and 35B serotype-switch variants of the ST156 clonal complex.

The authors concluded that PCV13+6C strains are still identified in 2017 but non-PCV13-type strains impose considerable burden. This well-annotated year 2017 WGS/strain dataset will prove useful for a broad variety of analyses and improved our understanding of IPD-causing strains in the post-PCV13 era.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.